4.5 Article

pANCA and ASCA in Children with IBD-Unclassified, Crohn's Colitis, and Ulcerative ColitisA Longitudinal Report from the IBD Porto Group of ESPGHAN

Journal

INFLAMMATORY BOWEL DISEASES
Volume 22, Issue 8, Pages 1908-1914

Publisher

OXFORD UNIV PRESS INC
DOI: 10.1097/MIB.0000000000000784

Keywords

pediatrics; IBDU; Crohn's colitis; UC; ANCA; ASCA; prediction

Funding

  1. GI-Nutrition Research Fund, Child Life and Health, University of Edinburgh
  2. SickKids Friends Foundation
  3. CICRA
  4. Medical Research Council [G0800675]
  5. Pediatric Research Foundation (Finland)
  6. Sigrid Juselius Foundation
  7. Helsinki University
  8. MRC [G0600329, G0800675] Funding Source: UKRI
  9. Medical Research Council [G0800675, G0600329] Funding Source: researchfish
  10. Medical Research Foundation [C0482] Funding Source: researchfish

Ask authors/readers for more resources

Introduction:No study to date has evaluated perinuclear antineutrophil cytoplasmic antibody (pANCA) and anti-Saccharomyces cerevisiae antibody (ASCA) in pediatric inflammatory bowel disease-unclassified (IBDU) as compared with Crohn's colitis (CC) and ulcerative colitis (UC), which represent the diagnostic challenge. We aimed to explore the diagnostic utility of serology and to assess whether serology can predict disease severity in these subgroups.Methods:This was a multicenter retrospective longitudinal study including 406 children with inflammatory bowel diseases (IBD) from 23 centers affiliated with the Porto group of European Society of Pediatric Gastroenterology, Hepatology and Nutrition (mean age 10.5 3.9, 54% males); 117 (29%) with CC, 143 (35%) with UC, and 146 (36%) with IBDU. Median follow-up period was 2.8 years (interquartile range, 1.6-4.2).Results:The most prevalent serologic profile in IBDU was pANCA-/ASCA- (41%), followed by pANCA+/ASCA- (34%) and pANCA-/ASCA+ (17%). pANCA-/ASCA+ differentiated well between CC versus IBDU (83% specificity, 96% positive predictive value [PPV]) and UC (97% specificity, 90% PPV) patients, albeit with a low negative predictive value (13% and 40%, respectively). pANCA+/ASCA- did not differentiate as well between IBD subgroups, but UC children with pANCA+/ASCA- had more often severe disease at diagnosis (36 [62%] versus 22 [38%], P = 0.033) and needed more often calcineurin inhibitors, biologics, or colectomy (25 [80%] versus 6 [20%], P = 0.026). In CC, double positivity for ASCA and not pANCA-/ASCA+ profile was associated with disease severity.Conclusions:Serology may have some role in predicting disease course and outcomes in colonic IBD, but its routine use needs to be supported by more studies. Serology cannot routinely be recommended for differentiating between IBDU versus CC or UC as a sole diagnostic criterion given its low diagnostic utility.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available